We evaluated the stability of human immunodeficiency virus (HIV) load markers from blood samples collected in VACUTAINER CPT or standard VACUTAINER brand tubes using sodium heparin or sodium citrate as anticoagulants. Quantitative plasma culture and p24 antigen concentrations were determined, and HIV RNA levels in plasma were measured by both reverse transcription-PCR-enzyme-linked immunosorbent assay (RT-PCR-ELISA) and branched DNA methods. All tubes were stored at room temperature for analysis at 2, 24, 48, and 72 h after the blood samples were drawn. No difference was seen between tube types with respect to the HIV titer in plasma or the positivity rate for all samples that demonstrated a fall in titer over time. Unbound p24 antigen levels in plasma decreased during the initial 48-h period in both tube types.
Immune complex-dissociated p24 antigen levels decreased in CPT tubes but not in standard VACUTAINER tubes. The HIV RNA copy number in plasma measured by RT-PCR-ELISA was stable in most subjects and was significantly higher in CPI tubes than in standard VACUTAINER tubes at 24 and 72 h after the blood samples were drawn. The branched DNA probe assay detected a significant decline in HIV RNA equivalents in plasma over 72 h in both collection tubes, the decline being more dramatic in the standard VACUTAINER tube than the CPI tube. Overall, interday variability suggests that samples collected for a particular assay should be processed at the same time after blood is drawn and that a particular tube type be used throughout a given study.
Blood samples collected during a multicenter clinical trial should be processed, stored, transported, and analyzed in a standardized manner. To reduce variation, sample handling at individual clinical sites should be minimal. To achieve this, a simple blood collection and transport system must be made available to clinical sites without biohazard facilities to efficiently process human immunodeficiency virus (HIV)-infected samples. Stability data for the collection system used must be known prior to the initiation of the protocol.
VACUTAINER CPT brand tubes contain an anticoagulant, a polyester gel barrier, and liquid density gradient medium which allow separation of plasma and peripheral blood mononuclear cells (PBMCs) from erythrocytes and granulocytes following a single 20-min centrifugation. Once they are separated, plasma and mononuclear cell fractions can be removed for analysis or storage or the tube can be shipped to a regional virology laboratory. The study described here was designed to compare the CPT tube with a standard VACUTAINER (V) tube for the postcollection stability of HIV viral load markers. Virus infectivity was measured by plasma culture. Virion HIV RNA quantification by RT-PCR-ELISA. The virionassociated HIV type 1 (HIV-1) RNA copy number was determined from 1-ml citrated plasma samples by a modification of the RT-PCR-ELISA-based quantitative assay described previously by Holodniy et al. (5) . The modifications included an additional low-speed centrifugation (30 min at 800 x g) to clarify the plasma and then centrifugation for 1 h at 23,000 x g at 4°C to pellet the virions. The supernatants were removed and the pellets were stored in 5 M guanidinium isothiocyanate at -80°C pending batch analysis by RT-PCR-ELISA.
HIV-1 RNA quantification by the bDNA assay. HIV-1 RNA was also quantified by bDNA signal amplification-based hybridization by using the Quantiplex HIV-RNA assay kit according to the manufacturer's instructions (Chiron Corporation, Emeryville, Calif.) (10, 12) . A similar technique has been used to evaluate hepatitis C virus in patients with HIV disease (11) . Virus was concentrated from duplicate 1-ml heparinized plasma specimens by centrifugation in a bench top microcentrifuge (Heraeus centrifuge model 17RS; rotor 3753; Heraeus Sepratech, South Plainfield, N.J.) at 23,500 x g for 1 h at 4°C. The virus pellet was extracted in a buffer containing proteinase K, lithium lauryl sulfate, and target probes complementary to the HIV-1 pol gene; this was followed by transfer of the extract to microwells coated with a capture probe. The RNA-probe complex was captured onto the surface of the microwell during an overnight incubation via hybridization of the solid-phase capture probe with a subset of the target probes. The wells were washed, and the bDNA amplifier molecule was hybridized to the immobilized target-probe complex; this was followed by hybridization of multiple alkaline phosphatase-labeled probes to each bDNA molecule. The complex was then incubated with a chemiluminescent substrate (dioxetane), and the light emission was measured in a luminometer (Chiron Corporation). The light emission was proportional to the amount of labeled probe bound to the captured target RNA (10) . The concentration of RNA in a specimen, expressed as HIV RNA equivalents per milliliter, was determined from a standard curve with a dynamic range of 1 x 104 to 1.6 x 108 HIV RNA eq/ml of plasma.
Unbound and ICD p24 antigen. Frozen heparinized plasma was batch thawed and tested for p24 antigen by using a commercially available ELISA kit according to the manufacturer's recommendations (Coulter Corporation). Immune complex-dissociated (ICD) p24 antigen was determined according to the manufacturer's instructions. p24 antigen concentrations were determined only on blood samples processed at 2, 24, and 48 h after collection.
Statistical analysis. All analyses were carried out by using the nonparametric, two-sided Wilcoxon signed-rank test. The assumption was made that the quantitative virologic markers to be measured would neither change over time nor differ between the two types of collection tubes used. 
RESULTS
The characteristics for the 15 HIV-infected patients involved with the present study are presented in Table 1 . Only 10 of the 15 subjects underwent complete testing; for 5 of the subjects, only cultures of plasma for HIV were performed. The average CD4 lymphocyte count was 123 ± 121 cells per mm3 (mean ± standard deviation). Seven of the subjects had not received any U.S. Food and Drug Administration-approved or investigational antiretroviral therapy in the previous 3 months, four had been receiving zidovudine for more than 1 year, and the remaining four had been on zidovudine or a zidovudinedidanosine combination for less than 1 year. Nine of the 15 subjects had symptomatic disease (CDC class B3 or C3) (1).
Plasma samples collected from 7 of the 15 subjects (47%) were HIV culture positive at hour 2 in both CPT and V tubes ( Table 2) . Those subjects whose plasma was culture positive either had received zidovudine for a minimum of 10 months or were receiving no therapy at all. All plasma samples that were negative in culture at hour 2 remained negative when tested at 24, 48, and 72 h postcollection. Viral titers in plasma decreased in 12 of 14 culture-positive samples at both the 24-and 48-h processing times when compared with the viral titers in the samples processed at hour 2. The noted decrease was highly variable (up to 5 dilutions in one instance), between sampling days, although in general the decrease varied by 1 to 2 dilutions. No difference in the change in titer was seen between the CPT and V tubes.
The absolute HIV RNA copy numbers in plasma measured by the RT-PCR-ELISA in nine subjects are presented in Table  3 . The mean RNA copy number was statistically higher in the CPT tubes than in the V tubes at 24 and 72 h, with P values of 0.05 and 0.02, respectively. Standard V tubes showed a trend toward a fall in the log RNA copy number after 24 h (P = 0.11), and the RNA copy number was significantly lower by hour 72 (P = 0.04). The CPT tubes, however, maintained 62% of the original log RNA copy numbers after an equal amount of time (P = 0.31).
Quantitative RNA data from the bDNA assay collected for samples from nine subjects in whom RNA levels were detectable are given in Table 5 . Unbound p24 antigen was detectable in 7 of the initial 10 subjects tested. By using ICD techniques, antigen was detectable in 9 of 10 subjects. Unbound p24 antigen concentrations fell in both tubes to 62 and 69% of the baseline values for CPT and V tubes, respectively, when measured at 48 h postcollection. By the ICD assay, the standard V tube maintained the concentration to the 48-h mark significantly better than the CPT tube did (P = 0.05). Data are means ± standard deviations for nine samples.
'Wilcoxon signed-rank, two-tailed. DISCUSSION Recently, the AIDS Clinical Trials Group Virology Committee reported their recommendation on the use of virologic assays for the detection of HIV in clinical samples (3). That group described the specimen requirements for determination of ICD p24 antigen, HIV culture of plasma for HIV, DNA PCR, and plasma RNA PCR. Although they provide references for the assay procedures and their indicated uses, no references were made to the origin of the sample collection, processing, and stability data. Coombs et al. (2) reported that the HIV titer in plasma remained unchanged up to 6 h postdraw when left as whole blood. In addition, they found that HIV RNA in plasma, when separated from whole blood, remained stable for up to 6 days. Overall, there is minimal published literature on the stability of HIV load markers with respect to sampling and processing and the effect of storing whole blood at room temperature to mimic transportation. In addition, this lack of data has left it up to investigators to blindly define the acceptable parameters for specimen collection and storage.
We reported on the stability of the HIV titer in plasma culture, the HIV RNA copy number in plasma determined by RT-PCR-ELISA and bDNA amplification technologies, and p24 antigen concentrations in specimens obtained in various blood collection tubes. In our investigation we evaluated a new collection device, the VACUTAINER CPT tube, and the standard tube. The benefits of the CPT closed-tube system include the limited exposure of personnel to the infected blood product at the clinical site, decreased sample processing time at both the clinic and the reference laboratory, and the stabilization of viral load markers in plasma.
The data presented here support the finding that VACU-TAINER CPT tubes maintained the HIV positivity in plasma culture rate longer than standard V tubes. Almost all samples demonstrated a fall in titer by 1 (9) reported that no change in the tissue culture infective dose over a 48-h period is observed when plasma is immediately separated from whole blood and then stored at 4°C. HIV RNA in plasma was shown to be more stable in the VACUTAINER CPT tube than in the regular V tube with respect to the change in the actual copy number as measured by both the RT-PCR-ELISA and the bDNA assay. In addition, both assays demonstrated that the signal was higher in the CPT tubes than in the standard V tubes at the baseline. Although we did not perform a large-scale, cross-sectional study, it may be possible that the CPT tube would increase the ability of clinicians to detect those people whose HIV-1 infection was previously undetectable by quantitative RNA techniques. We and others have previously reported the stability of HIV RNA in plasma as measured by RT-PCR-ELISA techniques in standard V tubes, although not in the VACUTAINER CPT system (6) . In addition, we presented here the first data on the stability of samples collected for the bDNA amplification assay. RNA equivalents for this assay were found to be consistently higher in the CPT tubes and decayed at a significantly lower rate than in the standard V tube. This lower signal decay rate may be explained by the immediate separation of neutrophils from PBMCs in the CPT tube or the better separation of platelets in the standard V tube (we are investigating this issue). Neutrophils have been shown to have a viricidal effect on HIV in vitro (7), and platelets may be bound with virus and could therefore lead to a lower RNA copy number (or equivalent) per milliliter of plasma if removed (8) . Thus, for the bDNA assay, the preferable blood collection system is the CPT tube. Further studies are under way to determine if anticoagulated plasma (citrate, EDTA, heparin) or serum is preferable for this assay.
As expected, our ability to detect p24 antigen was increased with the use of the ICD test. Both collection tubes demonstrated a decline in unbound p24 antigen concentrations at 48 h postcollection. In theory, this decline may be secondary to a release of p24 antibody by B cells, a decay in p24 antigen, or a change in p24 antigen epitope under sample storage conditions, thereby preventing normal complexing in the ELISA. We did detect a significant difference in ICD p24 antigen concentrations between the two types of collection tubes, but the standard V tube maintained the sample concentration for the 72-h sampling period. This result was not expected and is difficult to explain.
The data presented here support the fact that both collection tubes can be used to sample for HIV in plasma culture and HIV plasma RNA and for p24 antigen detection. We chose to study the effect of sample storage at room temperature in an attempt to mimic the conditions encountered in a multicenter clinical trial. Repeated sample mixing and the temperature changes observed in transport could not be standardized for the purpose of the present study and were not evaluated for their effects on viral marker stability. Given that one tube may produce a higher value than the other tube for a particular test, as with the RNA detection assays used in the present study, it would be best to perform an entire study with a particular type of tube. In addition, three of the tests performed in the present study, HIV plasma culture for HIV, bDNA, and p24 antigen concentration determinations, can be done from a single heparinized blood collection tube, while RNA PCR is performed from a sodium citrated sample to eliminate the effect of heparin on the PCR. With the observed decrease in plasma p24 antigen concentration and RNA signal over time, the length of time to sample processing, including storage, should be standardized. Although these detectable and potentially significant falls may be rectified by immediate separation and refrigeration of a plasma sample, this level of processing would limit the areas where clinical blood samples could be processed postcollection. Issues of personnel safety and the lack of biohazard containment equipment at clinical sites make the CPT tube an important device for sample collection.
